• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Oncology
    • Supply Chain
  • Awards
    • CRO Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Oncology
    • Supply Chain
  • Awards
    • CRO Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

GSK

GSK
Pharma

GSK allows generic versions of cabotegravir for HIV treatment

GSK has expanded its agreement with the Medicines Patent Pool, allowing generic production of cabotegravir as an HIV treatment in poorer nations.
Kevin Dunleavy Jul 15, 2025 2:16pm
FDA

As GSK eyes Blenrep's US return, FDA flags eye safety concerns

Jul 15, 2025 10:52am
Zantac

Delaware court rules against expert testimony in Zantac cases

Jul 11, 2025 12:10pm
Summer sunset with a red barn and silos in rural Montana with Rocky Mountains in the background

Respiratory royalty rally around rural COPD education drive

Jul 9, 2025 8:05am
Asia

RemeGen, Harbour, Datroway—Fierce Pharma Asia

Jun 27, 2025 8:37am
Gilead

Uptake of Gilead's Yeztugo will be swift, analyst says

Jun 25, 2025 2:51pm

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings